Description:A highly anticipated experimental drug for Alzheimer's disease, called bapineuzumab, wasn't effective at slowing memory loss in a large, late-stage clinical trial in patients with a high-risk genetic mutation. WSJ's Shirley Wang has been looking at the results.(3:01)